F2G is a clinical-stage biopharmaceutical company with operations in the UK, US, and Austria focused on the discovery, development and commercialisation of novel therapies to treat potentially life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides with a completely different mechanism from currently marketed antifungal agents. Orotomides have fungicidal activity against a broad range of rare and resistant fungal mold infections. Olorofim is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective including coccidioidomycosis. Olorofim is currently in a Phase 3 RCT study for invasive aspergillosis.